Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter prospective observational study to confirm the effectiveness and safety of trastuzumab deruxtecan for unresectable and/or metastatic breast cancer patients with HER2-low expression

Next Previous
Trial Profile

A multicenter prospective observational study to confirm the effectiveness and safety of trastuzumab deruxtecan for unresectable and/or metastatic breast cancer patients with HER2-low expression

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 23 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms HALLOW

Most Recent Events

  • 23 Dec 2025 New trial record
  • 08 Dec 2025 According to a Daiichi Sankyo Company media release, data from this study will be presented at the at the 2025 San Antonio Breast Cancer Symposium (#SABCS25) on December 10 to 12 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top